GUB-014295 by Gubra for Obesity: Likelihood of Approval

GUB-014295 is under clinical development by Gubra and currently in Phase I for Obesity.

Dec 20, 2023 - 18:00

GUB-014295 is under clinical development by Gubra and currently in Phase I for Obesity.

Read the original article

Tags:

Previous Article

UI-059 by Korea United Pharm for Reflux Esophagitis (Gastroesophageal Reflux Dis...

Meloxicam fast acting by Viatris for Post-Operative Pain: Likelihood of Approval

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Bristol Myers Squibb acquires Karuna Therapeutics for $14bn

Bristol Myers Squibb acquires Karuna Therapeutics for $...

Mar 20, 2024

Kezar and Everest enter lupus nephritis therapy development deal

Kezar and Everest enter lupus nephritis therapy develop...

Sep 21, 2023

Suicide hotlines shared data with Facebook, providers debate AI disclosure, and Uber Health expands

Suicide hotlines shared data with Facebook, providers d...

Jun 14, 2023